Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Harrow Secures US and Canadian Rights to Vevye
Harrow has recently announced a significant development by entering the prescription dry eye disease treatment market. The company has successfully struck a deal to acquire the commercial rights for Vevye (cyclosporine ophthalmic solution 0.1%) in both the United States and…
2023 Recap: Top 15 Firsts in Ophthalmology
In a year marked by groundbreaking achievements, the field of ophthalmology witnessed a series of historic firsts, pushing the boundaries of innovation and patient care. Here are the noteworthy milestones: Pioneering the integration of technology into glaucoma management, the world’s…
Biocon Receives UK approval for YESAFILI®
Biocon Biologics announced that YESAFILI®, a biosimilar of Aflibercept, has been granted marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. In September, YESAFILI® also received marketing authorization approval from the European Commission for the…
Aviceda’s IND Cleared by FDA for GA to AMD Treatment
Aviceda Therapeutics announced that the FDA has granted clearance for the IND for AVD-104. This clearance will allow the company to proceed with the initiation of Phase 2 clinical trials of its leading intravitreal ocular asset for the treatment of…
Patient Compliance: A Major Challenge for Ophthalmologists
According to the results of a recent LinkedIn survey conducted by our team, treating eye conditions can be a daunting task for medical professionals due to several challenges. Patient Compliance The survey asked attendees what their biggest challenge was when…
Top 5 Milestones in Ophthalmology History
In this article, we explore five significant milestones in the history of ophthalmology that have shaped the way we approach eye health and treatment. The ancient Egyptians, known for their advanced civilization and remarkable contributions to various fields, including medicine,…
FDA Calls for Study on Aldeyra’s Reproxalap in DED
Aldeyra Therapeutics announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for reproxalap, an investigational drug candidate designed for the treatment of dry eye disease.…
Study Reveals Why People with Albinism Have Poor Vision
People with albinism often have poor vision. A new study from the Netherlands Institute for Neuroscience reveals the underlying cause. In Europe, albinism occurs in 1 in 20,000 individuals. However, in some populations, it is much more common, affecting 1…
Reviving Hope for Amblyopia: Late-Stage Treatment
In children with amblyopia, often referred to as “lazy eye,” one eye exhibits weaker vision than the other due to various factors. This weaker eye may struggle with focusing, misalignment due to strabismus, or vision obstruction from conditions like cataracts…
Scientists Innovate Tech for Ischemic Retinopathy Treatment
Professor Byoung Heon Kang and his research team at the Department of Biological Sciences at Ulsan National Institute of Science and Technology (UNIST), in collaboration with Professor Dong Ho Park’s team at Kyungpook National University Hospital, have developed a novel…